ClinicalTrials.gg
Sign In

Hematologic Neoplasms clinical trials

The registry lists 1,444 studies for Hematologic Neoplasms across more than 10 countries. 420 are recruiting or about to start. 982 of them are mainly about Hematologic Neoplasms (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10. Counting its 2 narrower conditions too, such as Polycythemia Vera: 1,754 studies, 479 open.

ClinicalTrials.gov finds 14,387 studies for Hematologic Neoplasms. How that becomes 1,442 here

This page counts the studies the registry files under Hematologic Neoplasms, and those it files under no condition that list Hematologic Neoplasmsthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 14,387Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −309Filed under a narrower condition, counted on its own pagePolycythemia Vera 272 · Blastic Plasmacytoid Dendritic Cell Neoplasm 37
  3. −52List Hematologic Neoplasms as a condition, but the registry did not file them under itMost often written as “Transplant-Related Hematologic Malignancy” (7), “Advanced Hematologic Malignancies” (6), and “Lymphoid Hematological Malignancies” (4). The registry filed 22 of them under no condition at all, and the others under other conditions only, most often Leukemia, Myeloid, Acute (8) and Recurrence (8).
  4. −12,584Match it another way616 name it in the title, 11 in a keyword, and 11,957 by a synonym or other text the search reads.
  5. 1,442The count on this page

Get an email when these change. Save the Hematologic Neoplasms studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
567
Recruiting
313
Terminated
138
Active, not recruiting
122
Status unknown
120
Not yet recruiting
87

Phase

Phase 2
433
Phase 1
411
Phase 3
89
Early Phase 1
32
Phase 4
25

Where

United States
821
China
148
France
142
Italy
98
Canada
80
Spain
77

Who runs them

M.D. Anderson Cancer Center (99) · National Cancer Institute (NCI) (60) · Fred Hutchinson Cancer Center (28) · City of Hope Medical Center (25) · St. Jude Children's Research Hospital (22) · Novartis Pharmaceuticals (17) · Dana-Farber Cancer Institute (16) · Assistance Publique - Hôpitaux de Paris (16)

What is being tested here

Drugs under test in Hematologic Neoplasms studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Cyclophosphamide17352
Fludarabine10140
Venetoclax719
Thymoglobulin419
Azacitidine429
Busulfan3125
Melphalan3116
Bortezomib3110
Trametinib328
Thiotepa307

Drug classes tested here Alkylating agents 20 open · Antimetabolites 17 open · Tyrosine kinase inhibitors (TKIs) 17 open · Immune checkpoint inhibitors 5 open · Proteasome inhibitors 3 open

Coming up

33phase 3 studies under way
155studies finish main data collection within a year6 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 313 Hematologic Neoplasms studies recruiting now, 208 (66%) set no upper age limit and 78 (25%) stop at 75 or younger. 80 (26%) take children under 18. 1 (<1%) are for women only and 0 (0%) for men only; 34 (11%) take healthy volunteers.

Recruiting studies that take each age, of 313
AgeWomenMen
1063 (20%)63 (20%)
18292 (93%)291 (93%)
30292 (93%)291 (93%)
40289 (92%)288 (92%)
50289 (92%)288 (92%)
65287 (92%)286 (91%)
75264 (84%)263 (84%)
85225 (72%)224 (72%)

Across all 1,444 studies, recruiting or not: 27% stop at 75 or younger and 15% at 65; 24% take children; <1% are for women only and <1% for men only; 7% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Hematologic Neoplasms studies take

Of 159 phase 1 interventional studies under Hematologic Neoplasms, half reached primary completion within 51 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 151 mo28–78 · 159 studies43 mo30–78 · 95 studies56 mo28–88 · 64 studies
Phase 1/276 mo51–127 · 64 studies——
Phase 257 mo40–94 · 136 studies—59 mo42–95 · 114 studies
Phase 358 mo42–81 · 41 studies——
Interventional, no phase40 mo21–125 · 191 studies—40 mo21–125 · 185 studies
Observational74 mo34–322 · 186 studies—74 mo35–322 · 164 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 12, 2026.

Started recruiting8

Show 3 more

Results posted1

Stopped1

Newly registered12

Show 7 more

Studies

Recruiting first, then most recently updated. Showing 50 of 1,444. Browse all 1,444 → or search them.